1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals, Inc.

EIGRQ
Eiger BioPharmaceuticals, Inc.US flagOther OTC
8.50
USD
+0.50
- -
12.59MMarket Cap
Eiger BioPharmaceuticals, Inc.
EIGRQ
(Other OTC)

Recent

price

8.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
10.73
9.72
10.68
10.69
Revenue per Share
-367.01
-600.49
-530.86
-648.51
-1,865.83
-235.16
-145.9
-114.63
-92.5
-69.34
-29.98
-69.74
-50.78
-50.82
Basic EPS, GAAP
-294.71
-549.07
-414.56
-574.66
-1,285.57
-189.92
-132.05
-93.68
-84.38
-67.63
-106.12
-60.07
-50.66
-50.7
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
-3,461.99
-2,866.39
-2,805.25
-26,729.69
-381.3
-408.33
-374.54
-317.87
-326.68
-300.83
-315.06
-346.93
-347.19
Book Value per Share
- -
-1,062.48
-1,298.21
1,381.28
4,419.19
203.37
77.41
145.7
74.36
101.3
63.99
39.86
-9.79
-9.8
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
1
1
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
12
13
16
16
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-633.66
-687.78
-455.12
-455.12
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
1
Depreciation Expense
-7
-16
-20
-34
-13
-47
-42
-52
-70
-65
-34
-97
-75
-75
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-279.34
-717.71
-475.26
-475.26
Profit Margin (%)
- -
31
12
81
32
55
35
92
83
121
73
92
-15
-15
Working Capital
- -
- -
- -
10
- -
15
13
26
32
32
24
40
- -
- -
LT Debt
- -
24
9
72
32
41
23
67
56
95
72
55
-14
-14
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'23
Sep'23
Dec'23
ST Debt
- -
- -
41
LT Borrowings
40
41
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1
1
1
Market Capitalization
31
13
10

Working Capital

FRC

•

in mil. unless spec.
Jun'23
Sep'23
Dec'23
Total Current Assets
70
55
38
Cash, Cash Equivalents & STI
54
39
25
Accounts Receivable, Net
4
1
2
Inventories
1
1
2
Total Current Liabilities
17
17
53
Payables & Accruals
11
10
7
ST Debt
- -
- -
41
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
69.51%
-24.1%
-126.14%
Free Cash Flow
43.87%
19.42%
-10.28%
Net Income, GAAP
41.73%
28.32%
-22.54%
Sales/Revenue/Turnover
- -
- -
16.98%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
4
2
3
3
12
2022
3
4
4
3
13
2023
4
5
3
4
16

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
25.89
-16.95
-19.64
-19.2
-29.98
2022
-19.27
-15.25
-18.48
-17.11
-69.74
2023
-15.48
-14.02
-12.2
- -
-50.78

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Similar Companies
ALK-Abelló A/S (ALK-B.CO)
Eliem Therapeutics, Inc. (ELYM)
Ultimovacs ASA (ULTI.OL)
Enlivex Therapeutics Ltd. (ENLV.TA)
Tissue Regenix Group plc (TSSNF)
Xcell Therapeutics, Inc. (373110.KQ)
Business
I did not find relevant recent major company changes or other updated details specifically about Eiger BioPharmaceuticals, Inc. from the initial broad search results. I will conduct a more focused search specifically on Eiger BioPharmaceuticals, Inc. including their latest news, partnerships, acquisitions, product launches, and strategic updates.

Company News

APIChat

  • reuters.com

    Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar